Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)

Civil Hospices of Lyon

Status: Completed

Conditions: HIV-infected Patients

Treatments: Biological: lymphocytes immunophenotyping

Study type: Observational

Funder types: Other

Identifiers

NCT02827227

D21969

Details and patient eligibility

About

The objective was to identify factors associated with the normalization of the CD4/CD8 ratio (>=1) in patients with a history of primary HIV infection (PHI) and long-term combined antiretroviral therapy (cART).

Enrollment: 99 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

all HIV patients with a known history of PHI and a minimum of 2 years of effective cART (< 200 copies/mL) without interruption or virological failure

Exclusion criteria

Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH

Trial design

99 participants in 1 patient group

Primary HIV- Infected patients

Description:

Primary HIV- Infected patients with a minimum of 2 years of effective cART.

Treatment:

Biological: lymphocytes immunophenotyping